These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16823838)

  • 21. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.
    Czabanka M; Parmaksiz G; Bayerl SH; Nieminen M; Trachsel E; Menssen HD; Erber R; Neri D; Vajkoczy P
    Eur J Cancer; 2011 May; 47(8):1276-84. PubMed ID: 21396810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
    Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
    Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase.
    Schellmann N; Panjideh H; Fasold P; Bachran D; Bachran C; Deckert PM; Fuchs H
    J Immunother; 2012 Sep; 35(7):570-8. PubMed ID: 22892453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective targeted delivery of TNFalpha to tumor blood vessels.
    Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
    Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
    Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors.
    Li J; Hu P; Khawli LA; Yun A; Epstein AL
    Hybrid Hybridomics; 2004 Feb; 23(1):1-10. PubMed ID: 15000842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.
    Mortensen MR; Mock J; Bertolini M; Stringhini M; Catalano M; Neri D
    Oncotarget; 2020 Nov; 11(44):3972-3983. PubMed ID: 33216834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-cytokine fusion proteins for the therapy of cancer.
    Penichet ML; Morrison SL
    J Immunol Methods; 2001 Feb; 248(1-2):91-101. PubMed ID: 11223071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model.
    Tsai YS; Shiau AL; Chen YF; Tsai HT; Lee HL; Tzai TS; Wu CL
    Vaccine; 2009 Aug; 27(39):5383-92. PubMed ID: 19596413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
    Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
    J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
    Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
    Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
    Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
    J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
    Pasche N; Frey K; Neri D
    Angiogenesis; 2012 Mar; 15(1):165-9. PubMed ID: 22052195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
    Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
    Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-directed lymphocyte-activating cytokines: refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis.
    Makabe K; Asano R; Ito T; Tsumoto K; Kudo T; Kumagai I
    Biochem Biophys Res Commun; 2005 Mar; 328(1):98-105. PubMed ID: 15670756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.